Biogen launches late-stage study of galiximab

Biogen Idec has begun a late-stage trial for galiximab, an investigational anti-CD80 monoclonal antibody for lymphoma. The trial will compare a combination of galiximab and rituxan with a combination of rituxan and a placebo. Researchers plan to enroll 700 volunteers in the study.

"The median survival time for patients with follicular non-Hodgkin's lymphoma is 7-10 years, and relapses are common, therefore, we're aiming to delay progression as long as possible," said Patrick Stiff, M.D., the director of Loyola University Medical Center's Cardinal Bernardin Cancer Center, and professor of medicine and pathology at Stritch School of Medicine, Loyola University Chicago. "Galiximab may offer an additional therapeutic option for patients, particularly for patients who have failed or relapsed on other therapies."

- see the release on the trial

Related Articles:
Biogen Idec considering sale of cancer drug. Report
Genentech and Biogen Idec in talks over Rituxan. Report